黄芩苷磷脂复合物口服给药大鼠体内动力学研究  

Pharmacokinetics study of baicalin-phospholipid complex in rat

作　　者：李楠[1] 冯玲玲[1] 蒋学华[2] 杨明[1,3] 

机构地区：[1]成都中医药大学药学院,四川成都611137 [2]四川大学华西药学院,四川成都610041 [3]江西中医药大学中药现代制剂教育部重点实验室,江西南昌330004

出　　处：《时珍国医国药》2017年第11期2568-2570,共3页Lishizhen Medicine and Materia Medica Research

基　　金：国家自然科学基金(81673615)

摘　　要：目的比较研究黄芩苷、黄芩苷磷脂物理混合物及黄芩苷磷脂复合物经口服吸收特性;并评价黄芩苷磷脂复合物的生物利用度。方法大鼠口服或静脉给药后,分别于不同时间点取血及分离脑组织;采用高效液相色谱法测定血浆及脑组织中黄芩苷浓度。结果黄芩苷磷脂复合物经口服给药后血浆及脑组织中AUC_(0～480)高于黄芩苷组及黄芩苷磷脂物理混合物组。结论当黄芩苷制备成磷脂复合物后,口服给药后能提高其生物利用度,并增加其在脑组织中的富集。Objective We used animal models to comparise the pharmacokinetics characteristics of baicalin, baicalin - phospho- lipid complex as well as a physical mixture of both. And also we evaluated the oral bioavailability of baicalin - phospholipid com- plex. Methods After oral or intraveuous administration, the plasma and brain tissue of the rat had been collected according to the different time points. Drug concentration in samples were detected by high performance lipid chromatography （HPLC） . Results The plasma and brain tissue AUC value of baicalin - phospholipid complex has been significantly increased by comparing with the baicalin and the physical mixture. Conclusion By being made into Phospholipid complex, it can improve the oral bioavailability of baicalin and increase the content of baicalin in brain.

关 键 词：黄芩苷 磷脂 口服生物利用度 脑分布 

分 类 号：R285.5[医药卫生—中药学]